*💊 Divi’s Lab Delivers Strong Q3 Growth!* 🔸 Revenue is up ~25% YoY to ₹2319 crore, driven by Custom Synthesis (CS) up 44% and APIs up 8.4%. 🔸 EBITDA is up ~52% YoY to ₹743 crore, with margins expanding to 32% (+568 bps). 🔸 PAT is up ~65% YoY to ₹589 crore. *💡Our View:* 🔸 Strong CS growth from phase-three project commercialization & new opportunities. 🔸 GLP-1 potential with advanced peptide synthesis capabilities. 🔸 API volumes are up despite pricing pressure. 🔸 ₹650-700 crore CS project investment set for 2027. 🔸 Kakinada project Phase-I production is underway, boosting capacity. Drop a 👍 & 🔄 to spread the insights! Disclaimer: bit.ly/full-disclaimer